Header Logo

Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.

Hussain A, Ramsey D, Lee M, Mahtta D, Khan MS, Nambi V, Ballantyne CM, Petersen LA, Walker AD, Kayani WT, Butler J, Slipczuk L, Rogers JG, Bozkurt B, Navaneethan SD, Virani SS. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.

View in: PubMed